NCT00352131View on ClinicalTrials.gov

Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors

PHASE1CompletedINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

February 28, 2005

Primary Completion Date

December 31, 2009

Study Completion Date

December 31, 2009

Conditions
Non-colorectal CancerPancreatic Cancer
Interventions
DRUG

HuC242-DM4

Dose escalation study to define maximum tolerated dose. Doses will vary per cohort. Patients will receive an IV infusion once every three weeks.

Trial Locations (2)

78229

South Texas Accelerated Research Therapeutics, San Antonio

78245-3217

UT Health Science Center, San Antonio

Sponsors

Lead Sponsor

ImmunoGen, Inc.
All Listed Sponsors
lead

ImmunoGen, Inc.

INDUSTRY

NCT00352131 - Maytansinoid DM4-Conjugated Humanized Monoclonal Antibody huC242 in Treating Patients With Solid Tumors | Biotech Hunter | Biotech Hunter